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Abstract
Background: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in
China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the
incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in
China.
Methodology/Principal Findings: In a population-based prospective study, we monitored 4,304 TB patients receiving
directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative
incidence of 2.55% (95% Confidence Interval [CI], 2.04%–3.06%). Nausea, vomiting and anorexia were the top three most
frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe
hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to
respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI.
Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication
administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12
(11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48
(46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a
9.25-fold (95%CI, 5.69–15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95%CI,1.23–3.60) risk of
prolonged intensive treatment phase.
Conclusions/Significance: ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI
and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are
warranted in order to enhance the diagnosis and the prevention of ATLI.
Citation: Shang P, Xia Y, Liu F, Wang X, Yuan Y, et al. (2011) Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug
Induced Liver Injury (ATLI) in China. PLoS ONE 6(7): e21836. doi:10.1371/journal.pone.0021836
Editor: Adithya Cattamanchi, San Francisco General Hospital, University of California San Francisco, United States of America
Received January 16, 2011; Accepted June 10, 2011; Published July 5, 2011
Copyright:  2011 Shang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the China Program for the Global Fund to Fight TB (NO:TB07-030). The funder had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: siyan-zhan@bjmu.edu.cn
Introduction
Tuberculosis (TB) continues to be a major health problem, with
9.4 million incident cases and 1.7 million deaths globally in 2009
[1]. China ranked second on the list of the top five TB endemic
countries in terms of incident cases: India, China, South Africa,
Nigeria and Indonesia. China (1.1–1.5 million) and India (1.6–2.4
million) combined accounted for 35% of all TB cases worldwide in
2009 [1]. In view of the seriousness of the problem, China
established the China National Tuberculosis Prevention and
Control Scheme (CNTS) in 1990 and has been implementing
directly observed treatment strategy (DOTS) since 1991, which
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21836
constitutes the cornerstone of the current strategy for TB control
and covers the entire population of China [2,3]. The key com-
ponent of DOTS strategy is the standard anti-TB short course
chemotherapy regimen, which requires continually taking drug
combinations of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z),
Ethambutol (E) and Streptomycin (S) every other day for 6–9
months [4].
Although these anti-TB drugs have shown that they are able to
contain and kill Mycobacterium tuberculosis effectively, they are known
to induce various adverse effects, including liver injury, skin
reactions, gastrointestinal and neurological disorders [5,6]. Anti-
tuberculosis drug induced liver injury (ATLI) is one of the most
important and serious adverse effects [7,8], which accounts for more
than 7.0% of the overall adverse effects [9,10]. The incidence of
ATLI during standard multi-drug TB treatment has been reported
varying from 2.0% to 28.0% according to different populations and
definitions [7]. Moreover, ATLI diminishes the effectiveness of anti-
TB treatment, as they may cause non-adherence, and further leads
to treatment failure, recurrence or the emergence of drug-resistance
[7,11,12]. These negative consequences could significantly impair
the overall effects of TB epidemic control.
In order to identify the adverse events earlier and provide timely
intervention, it is critical to understand the clinical features
of ATLI, such as the time of onset, severity, common clinical
symptoms, and its potential outcomes. Despite DOTS two decades
of implementation in China the CNTS does not include detailed
standard operating procedures regarding diagnosis and manage-
ment of possible ATLI. Therefore, we conducted this population-
based prospective study among patients with positive TB smear
and those who have received DOTS treatment. The aim of this
study was to estimate the incidence of ATLI, better understand its
clinical features, and more importantly, to evaluate its impact on
anti-TB treatment. We believe that the findings of this study will
provide additional clinical guidance to improve TB treatment and
enhance monitoring and control of the TB epidemic in China.
Methods
The prospective study was approved by the Ethics Committee
of Center for Tuberculosis Control and Prevention of China.
Written informed consent was obtained from every participant or
surrogate before enrolment.
Patient’s enrollment
This study consists of a cohort of patients with pulmonary TB
and who have received DOTS treatment in four geographically
and economically diverse areas of China. This cohort was
previously established in the study entitled ‘Anti-tuberculosis
Drugs induced Adverse Reactions in China National Tuberculosis
Prevention and Control Scheme Study’ (ADACS) [2]. In brief,
between October 2007 and June 2008, 6,460 smear-positive
patients who receive standard short-course chemotherapy recom-
mended by CNTS were initially identified in 52 counties of 4
provinces using the stratified, cluster and probability proportional
to size (PPS) sampling method. Among them, 155 patients did not
meet the study inclusion criteria and 1,817 patients did not
respond to the study. Therefore, a total of 4,488 patients were
enrolled into the cohort. The differences in terms of age and sex
between the 4,488 remainders and 1,817 non-responders were not
statistically significant (Data not shown).
Investigation and monitoring
At the enrollment, eligible patients were interviewed with a
questionnaire that collects information on demography, medical
history, co-morbidities, diagnosis of TB, previous anti-TB
treatment and current use of medication. During the study, the
patients were asked to take a list of laboratory examinations prior
to the initiation of anti-TB treatment, and repeat again during 1
to 2 months following the initiation of treatment. The lab exam-
inations included blood and urine routine tests, serum alanine
aminotransferase (ALT), aspartate aminotransferase (AST) and
total bilirubin (TBil) tests, renal function tests, and hepatitis B
surface antigen (HBsAg) tests. For those patients with suspected
ATLI, a third examination was conducted. All tests were com-
pleted at the local decentralized laboratories of Center for Disease
Control and Prevention (CDC) in China using uniform reagents
and equipments corrected with standard sample from China
national CDC laboratory.
Patients receiving primary TB treatment were monitored for 6
months, while patients with re-treatment TB were monitored for 8
months. The first 2-month period was defined as the intensive
treatment phase, in which primary and re-treatment patients took
HRZE and HRZES combination, respectively. The subsequent 4
or 6-month period was defined as the consolidation treatment
phase, in which patients took HR and HRE combination res-
pectively. According to CNTS, patients whose status does not
change to negative for smear results during the intensive treatment
phase needed to extend the intensive phase by 1 month.
During the monitoring period, patients were instructed to fill in
the ADACS calendars, which were designed to record patients’
self-reported sign/symptoms and drug usages. The listed feelings
were discomforts, including nausea, vertigo, headache, diarrhea,
arthralgia, paresthesia, visual and auditory abnormal feelings.
Meanwhile, the supervising doctors monitored patients for hepa-
totoxicity symptoms according to DOTS and check the ADACS
calendars every other day. The patients were asked to report to
their supervising doctors once they could no longer bear the
discomfort as a result of treatment or had symptoms of hepatitis
(such as nausea, anorexia, vomiting, diarrhea, icterus, etc.). If the
supervising doctors suspected the cause was ATLI, the patients
would be referred to CDC doctors for further examinations and
ATLI investigations. The ATLI investigation procedure would be
initiated as well if patients had abnormal lab results within 1 to 2
months following the anti-TB treatment, even if patients did not
experience any notable symptoms.
The Center for Drug Reassessment (CDR) of Chinese State
Food and Drug Administration was responsible for adjudicating all
the suspected ATLI cases, which were submitted online by each
study site. National Adverse Drug Reactions Monitoring system of
the CDR checked the report, evaluated the causality of drugs and
events, and confirmed the ATLI status of the patient. During the
adjudication process, the causality assessment followed the
standards developed by WHO Uppsala Monitoring Centre system
[2] which classifies the association as certain, probable/likely,
possible, unlikely, conditional/unclassified or inaccessible/unclas-
sifiable.
Once a suspected ATLI was identified, the investigator would
trace the patient’s ATLI treatment, prognosis, and clinical fea-
tures, as well as the outcome of anti-TB treatment. In this study,
Anti-TB treatment outcomes were recorded and classified into two
categories: successful outcomes (defined as the completion of
treatment and patients being cured) and unsuccessful outcomes,
including treatment failure, deaths of patients, default or patients
being transferred out [13].
Assessment of ATLI
In this study, the criteria for ATLI diagnosis was not only based
on the definition of hepatotoxicity developed by American
Study on Anti-Tuberculosis Induced Liver Injury
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Thoracic Society (ATS) [14], but also took into account the
various definitions published in previous studies [7,15–17], as well
as the diagnosis criteria developed by the CDR of Chinese State
Food and Drug Administration. Specifically, ATLI was diagnosed
when there is an increase in serum ALT or AST that was greater
than three times of the upper limit of normal (ULN), or in TBil
greater than two times of the ULN, when other causes were
excluded: new viral hepatitis infections, other potentially hepato-
toxic medications that would confound the picture, alcohol
consumption, other liver diseases, and/or drug use. All assess-
ments were double checked by two experienced physicians. The
severity of hepatotoxicity was classified according to the WHO
Toxicity Classification Standards [7]. Based on this definition,
severity of hepatotoxiciy was considered as follow: mild (3 times
ULN,ALT or AST#5 times ULN, or 2 times ULN,TBil#5
times ULN) and severe (ALT or AST or TBil.5 times ULN).
Statistical methods
The baseline characteristics of participants were described as
median (inter-quartile range, IQR) for continuous variables (not
subject to normal distribution), and percentages for categorical
variables.
The cumulative incidence was calculated using Kaplan Meier
method to deal with the censored data. Clinical features and
impact on anti-TB treatment of ATLI were reported using
descriptive analysis. In this study, the estimated incidence of ATLI
was standardized by age and sex using two reference populations
[2]: one population from the 4th national TB epidemiology
investigation of China in 2000, and the other from national TB
epidemic surveillance database of 2008.
The potential impact of ATLI on the length of intensive
treatment period, the anti-TB treatment effects and clinical
outcome were assessed with relative risk (RR), attributable risk
proportion (AR%) and population attributable risk proportion
(PAR%). AR% is the percent of the incidence of an outcome in the
exposed that is due to the exposure. PAR% is the percent of the
incidence of an outcome in the population including both exposed
and non-exposed population that is due to exposure.
Because this study was designed to allocate the same number of
patients in each province and then did PPS sampling in county
level, a sample weight was used in the calculation and comparison
of ATLI incidence rate. Sample weight was calculated in SPSS
procedure of weight according to total TB patients in each
province in 2006, which was also used in the PPS sampling.
The statistical analyses were performed using SPSS for
Windows (version 13.0; SPSS Inc.). A two-sided P value less than
0.05 was set as the significant level.
Results
Characteristics of participants
In the 4,488 recruited patients, 129 patients dropped out during
the monitoring, 23 patients died due to TB, and 32 died due to
other reasons including heart disease, cancer and accidents. As a
result, 4,304 patients completed the study, with a median observa-
tion time of 184 days. There were no statistically significant
differences in terms of age and sex between the 4,304 participants
and the 129 patients who dropped out (Data not shown). The
characteristics of 4,304 patients at baseline were shown in Table 1.
All 4,304 participants received at least 2 times of the ALT, AST
and TBil tests. After starting anti-TB treatment, 206 patients had
greater than 1 time of UNL elevation of ALT, 58 patients had
greater than 1 time of UNL elevation of AST, and 9 patients had
greater than 1 time of UNL elevation of TBil (Table 2).
Table 1. Baseline characteristics of 4304 patients with tuberculosis smear positive.a
Category Subcategory Result
Age, median years (IQR) 42.00 (29.00–55.00)
Male sex, number (%) 3082 (71.60%)
Weight, median kg (IQR) 52.70 (48.00–58.00)
Education status, number (%) None/elementary school 1895 (44.03%)
Secondary school 2260 (52.51%)
College/higher 135 (3.14%)
missing 14 (0.32%)
Type of treatment, number (%) Primary treatment tuberculosis 3556 (82.62%)
Re-treatment tuberculosis 748 (17.38%)
HBsAg, number (%) Positive 469 (10.89%)
Negative 3613 (83.95%)
Unknown 222 (5.16%)
History of other diseases, number (%) Diabetes 51 (1.18%)
Liver diseaseb 17 (0.40%)
Biliary tract diseasec 6 (0.14%)
Nephropathy 17 (0.40%)
Gastroenteropathy 40 (0.93%)
Others 103 (2.40%)
aAbbreviation used in table: IQR, inter quartile range.
bIncluding hepatitis B/C, alcohol liver disease, hepatapostema, hepatic cyst, hepatocirrhosis and schistosomiasis.
cIncluding cholecystitis and cholelithiasis.
doi:10.1371/journal.pone.0021836.t001
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Incidence and clinical features of ATLI
Among patients with abnormal ALT, AST or TBil level, 106
were diagnosed with ATLI, and the cumulative incidence of ATLI
was 2.55% (95% Confidence Interval [CI], 2.04%–3.06%). The
incidence of ATLI was 2.58% and 2.42% respectively after being
standardized by age and sex using standard population.
Of the 106 ATLI cases, further causality assessment revealed
that 17 cases (16.04%) were identified as certain, 65 (61.32%) as
probable and 24 (22.64%) as possible. 71.59 percent of ATLI cases
were identified within 2 months after starting anti-TB treatment.
The median interval in days between the initiation of TB
treatment and the detection of ATLI was 52.50 (IQR:30.00,
63.00) for all patients, 42.50 (IQR:29.25, 61.75) for primary and
61.00 (IQR:53.25, 68.25) for re-treatment TB patients. The
difference between primary and re-treatment TB patients was not
statistically significant (P = 0.29).
In terms of the severity of ATLI, 65 (61.32%) cases had mild
hepatotoxicity and 41 (38.68%) had severe hepatotoxicity. There
was no significant difference with respect to the severity of ATLI
between primary and re-treatment TB patients (P = 0.30).
Among the 106 ATLI cases, nausea (41.51%), vomiting (39.62%)
and anorexia (24.53%) were the top three most frequently reported
symptoms (Table 3). 35 patients (33.02%), including 27 with mild
hepatotoxicity and 8 patients with severe hepatotoxicity, did not
have any notable clinical symptoms. There was no significant
difference in terms of demographic characteristics between patients
with and without clinical symptoms (P.0.05).
In all the 106 ATLI cases, 88 (83.02%) sought medical advice.
78 (73.58%) received further medical examinations, 85 (80.19%)
received medical treatment and 17 (16.04%) were hospitalized.
Regarding the prognosis of ATLI, 84 cases (79.25%) recovered
(ALT test turned normal, and clinical symptoms disappeared), 18
(16.98%) improved (ALT test turned normal, and clinical sym-
ptoms improved), 2 (1.89%) patients failed to the treatment with
continued abnormal ALT, and 2 patients (1.89%) died of ATLI.
When comparing the 17 ATLI in-patients (including 2 died in
hospital) with the 89 ATLI patients that were not hospitalized, it
was found that the patients who were required for hospitalization
had an earlier onset t (35 days vs. 56 days), although the difference
was not significant (P = 0.21) (Table 4). After the start of anti-TB
treatment, a higher percentage of in-patients presented symptoms,
particularly anorexia, as compared to that in those without hos-
pitalization (94.1% vs. 61.8%) (P= 0.01).
Impact on anti-TB treatment of ATLI
Of all the 106 ATLI cases, 74 (69.81%) cases changed their anti-
TB treatment, including 4 (3.77%) with changes in medication
administration, 21 (19.81%) had drugs replacement, 54 (50.94%)
interrupted the TB treatment, and 12 (11.32%) discontinued the
TB treatment. The percentage of changes of anti-TB treatment
was 61.54% in patients with mild hepatotoxicity and 82.93% in
patients with severe hepatotoxicity, and the difference between the
two groups was statistically significant (P = 0.02).
When analyzing the impact of ATLI on anti-TB treatment,
three patients had to be excluded because they discontinued
the treatment after the onset of ATLI and could not be followed
up for TB treatment outcomes. Of the remaining 103 cases (94
unchanged and 9 discontinued anti-TB treatment cases), 53
(51.46%) cases had TB cured in time, 48 (46.60%) cased had
therapy prolonged, and 2 (1.94%) died. In addition, recovery rate
was 96.88% in 94 unchanged as compared to only 25.00% in 9
patients with discontinued anti-TB treatment patients (P,0.01).
Compared with non-ATLI patients, ATLI patients had 9.25-
fold (95% CI, 5.69-15.05) increased risk of developing unsuc-
cessful treatment outcomes and 2.11-fold (95% CI, 1.23–3.60)
increased risk of prolonging intensive treatment phase (Table 5).
PAR % for unsuccessful treatment outcomes and prolonged
intensive treatment phase was 16.58% (95% CI, 10.16–25.30)
and 2.57% (95% CI, 0.54–5.82) for ATLI and non-ATLI
patients, respectively.
Discussion
To our knowledge, this is the first multi-center population-based
prospective study of ATLI to provide data on the incidence,
clinical features and its impact on anti-TB treatment. The study
Table 2. Elevation of ALT/AST and TBil after starting anti-TB
treatment in TB patients by grade.a
Grade Relative to ULN No. of patients Percentage(%)
ALT
1 .1 times the ULN 58 28.15
2 .2 times the ULN 59 28.64
3 .3 times the ULN 49 23.79
4 .5 times the ULN 40 19.42
Sub-total 206 100.00
AST
1 .1 times the ULN 32 55.17
2 .2 times the ULN 18 31.04
3 .3 times the ULN 7 12.07
4 .5 times the ULN 1 1.72
Sub-total 58 100.00
TBil
1 .1 times the ULN 0 0.00
2 .2 times the ULN 6 66.67
3 .3 times the ULN 3 33.33
4 .5 times the ULN 0 0.00
Sub-total 9 100.00
aAbbreviation used in table: ALT, alanine aminotransferase; AST, aspartate
aminotransferase; TBil, total bilirubin; ULN, upper limit of normal.
doi:10.1371/journal.pone.0021836.t002
Table 3. The frequency of symptoms in 106 ATLI cases.a
Symptoms Frequency (%)
Nausea 44 (41.51)
Vomiting 42 (39.62)
Anorexia 26 (24.53)
Dizziness 26 (24.53)
Abdominal symptoms (abdominal pain/discomfort/diarrhea) 24 (22.64)
Rash/pruritus 20 (18.87)
Fatigue 19 (17.92)
Icterus/jaundice 4 (3.77)
Dark urine 1 (0.94)
No clinical symptoms 35 (33.02)
aAbbreviation used in table: ATLI, Anti-tuberculosis Drug Induced Liver Injury.
doi:10.1371/journal.pone.0021836.t003
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population represented one of the largest and most diverse co-
horts of TB patients receiving WHO recommended anti-TB
treatment.
Incidence of ATLI
Based on ATLI diagnosis criteria, the present study found a
2.55% cumulative incidence of ATLI in Chinese population
receiving standard DOTS anti-TB treatment. This was lower than
the rates reported in previously published studies that applied
similar hepatotoxicity definitions, namely, 3.0% in Canada (Asia
population accounted for 42%) [6], 5.0% in Hong Kong [15],
5.3% in Singapore [16] and 16.1% in Taiwan [17]. The lower
ATLI incidence may be attributed to the study setting. Our study
was population-based while others were hospital-based [6,15,17].
In hospital-based studies, the participants were likely to have more
complex and severe diseases and were monitored more frequently,
thus they had greater chances to reveal hepatotoxicity. Moreover,
the ethnicity and genetics might play an important role. The
Canada study [6] included non-Asia populations, having different
genetic background. Several genetic polymorphisms in drug
metabolizing enzymes were associated with ATLI, such as slow
acetylator satus (N-acetyl-transferase 2), a glutathione S-transfer-
ase M1 homozygote mull genotype and cytochrome P4502E1c1/
c1 genotype [18]. Thirdly, the prevalence of the virus infection
also influences the incidence of ATLI, such as HIV and HCV.
Literature suggests that the relative risk of developing drug-
induced hepatitis was fivefold for hepatitis C patients, fourfold for
HIV positive patients, and 14.4-fold for patients co-infected with
hepatitis C and HIV. Unfortunately, our studies did not test HIV
and HCV for every participant [19].
It should be noted that the cumulative incidence of ATLI was
1.84% in this study when only using the hepatotoxicity definition
of ATS [14]. According to ATS, the hepatotoxicity definition does
not include AST elevation. Moreover, asymptomatic individuals
with ALT.3–5 times ULN are not considered to have
hepatotoxicity. Actually, there are many definitions for drug-
induced hepatotoxicity in various journals [7,14–17]. In order to
enable our study to be comparable with previous studies, we used
the most frequently cited definition in those studies. In particular,
the hepatotoxicity is defined as a treatment-emergent increase in
transaminase greater than three or five times the upper limit of the
normal, with or without symptoms of hepatitis, respectively.
Table 4. The pattern of 17 ATLI in-patientsa and 89 non-hospitalized ATLI patients in 106 ATLI cases.b
Category Subcategory ATLI in-patients non-hospitalized ATLI patients P value
ATLI onset time, median days (IQR) 35.00 (25.50,58.50) 56.00 (30.00–63.50) 0.21
ALT .5 times the ULN, number (%) 10 (62.5) 30 (41.1) 0.12
#5 times the ULN, number (%) 6 (37.5) 43 (58.9)
AST .5 times the ULN, number (%) 0 (0.0) 1 (12.5) -
#5 times the ULN, number (%) 0 (0.0) 7 (87.5)
TBil .5 times the ULN, number (%) 0 (0.0) 0 (0.0) -
#5 times the ULN, number (%) 1 (100.0) 8 (100.0)
With symptom, number (%) 16 (94.1) 55 (61.8) 0.01
Nausea, number (%) 11 (68.8) 28 (50.9) 0.21
Vomiting, number (%) 10 (62.5) 27 (49.1) 0.35
Anorexia, number (%) 10 (62.5) 19 (34.6) 0.04
a17 ATLI in-patients included 2 died of ATLI.
bAbbreviation used in table: ATLI, Anti-tuberculosis Drug Induced Liver Injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, total bilirubin; ULN,
upper limit of normal.
doi:10.1371/journal.pone.0021836.t004
Table 5. Relative risk and attributable risk proportion for anti-TB treatment between ATLI and non-ATLI anti-TB treatment cases.a
Result
Category Subcategory ATLI Non-ATLI RR (95% CI) AR %d (95% CI)
Intensive treatment phaseb Prolonged 17 (16.19%) 323 (7.71%) 2.11 (1.23, 3.60) 52.51 (18.81, 72.22)
Un-prolonged 88 (83.81%) 3864 (92.29%)
Smear result at 2 monthsc Negative converted 94 (91.26%) 3929 (94.54%) 1.56 (0.77, 3.17) 35.91 (230.35, 68.48)
Un-negative converted 9 (9.74%) 227 (5.46%)
Clinical treatment outcome Unsuccessful outcomese 16 (15.09%) 67 (1.60%) 9.25 (5.69,15.05) 89.19 (82.42, 93.36)
Successful outcomesf 90 (84.91%) 4131 (98.40%)
aAbbreviation used in table: TB, tuberculosis; ATLI, Anti-tuberculosis Drug Induced Liver Injury; RR, relative risk; AR%: attributable risk proportion.
bIntensive treatment phase: the number of patients was 4292, because 12 patients missed data.
cSmear result at 2 months: the number of patients was 4259, because 45 patients missed smear examination.
dAR%: it is the percent of the incidence of an outcome in the exposed that is due to the exposure.
eUnsuccessful outcomes: A sum of treatment failure, died, default and transfer out.
fSuccessful outcomes: A sum of cure and treatment completed.
doi:10.1371/journal.pone.0021836.t005
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Clinical features of ATLI
71.59% of patients in this study developed ATLI during the first
2-month period after the treatment initiation, the median time
elapsed from the initiation of anti-TB treatment to ALT elevation
was 52.50 days. The median onset time of ATLI was longer as
compared to what was reported in hospitalized TB patients. For
example, a median onset day of 14 days and 15 days was reported
in an Iran study [20] and a Turkey study [21]. Their results might
be more receivable because hospitalized patients were visited and
monitored more closely and precisely. The median onset time
reported in our study was also longer than the 38 days reported in
a community-based cohort study in Singapore [16]. The true
ATLI onset time might be earlier than our estimation, because the
current median days of detection could be impacted by the timing
of ALT, AST and TBil tests during 1 to 2 months. In fact, 58.5%
of the patients had the 2nd test 1 month after treatment initiation
and 41.5% had it 1 month within treatment initiation.
Besides, our study indicated many ATLI patients experienced
nausea, anorexia and vomiting. Although these symptoms are not
specific to ATLI diagnosis [22], they might help clinicians be more
cautious about ATLI. This could be helpful to clinicians working
in developing countries, where ATLI diagnosis often relies on
observation of clinical symptoms, as laboratory test may not be
available [7]. On the other hand, other studies suggested that
asymptomatic transaminase elevations occur in 20% of patients
treated with standard anti-TB regimens [23–25], while in our
study, 33.02% of ATLI patients, including 8 severe hepatotoxicity,
did not present any clinical symptoms. Liver injury could be fatal
when it is not recognized early or therapy is not interrupted in
time [7]. Therefore, if available, routine monthly liver function
monitoring is highly suggested for patients receiving anti-TB
treatment in order to identify asymptomatic ATLI so as to apply
appropriate intervention in time. However, monthly liver function
monitoring is costly and could be difficult to perform among all
TB patients in China, a more practical approach is to identify
individuals who present some risk factors that are known to cause
ATLI and monitor them closely. As revealed by literature [7,8,14],
risk factors for ATLI include advanced age (above 60 years),
female sex, malnutrition, HIV-infection, pre-existent liver disease,
alcohol abuse, and concomitant use of other hepatotoxic drugs.
Impact of ATLI on anti-TB treatment
Adherence to DOTS is critical in managing patients with active
TB, because any change of anti-TB treatment will result in a
suboptimal treatment response, and further reduce treatment
effectiveness [7]. In our study, 69.81% of ATLI patients had to
change their anti-TB treatment. Moreover, the magnitude of
impact on the anti-TB treatment seemed to be related to the
severity of the event. For instance, the percentage of changes of
anti-TB treatment increased from 61.54% in mild hepatotoxicity
patients to 82.93% in severe hepatotoxicity patients. 16.58% of
unsuccessful treatment outcomes in our study might be attributed
to ATLI. That is to say, if we could prevent the occurrence of
ATLI, the percentage of patients with unsuccessful treatment
outcomes would be decreased by 16.58%. Given that 1,000,000
new TB cases arise in China every year, over 25,000 patients
might develop ATLI according to the ATLI incidence estimate in
this study. If we could eliminate impact of ATLI, we would have
prevented 4,228 TB patients from unsuccessful treatment
outcomes. According to the WHO report, one patient remaining
in mycobacterium transmittable status could possibly infect 10 to
15 more people in 12 months [2]. Therefore, preventing and
minimizing the negative impact of ATLI to enhance the rate of
successful TB treatment plays an important role in the overall
efforts of the TB epidemic control in China.
Timely identification and appropriate intervention of ATLI are
important. The guidelines for management of ATLI [26–28]
advise TB patients to be treated under supervision and to examine
liver function at signs or symptoms of hepatotoxicity. When ATLI
diagnosis is confirmed, TB treatment should be interrupted in a
timly manner and reintroduced until after the ATLI is resolved.
There is no explicit suggestion to TB patients in China. Therefore
more studies are needed to discuss the pattern of abnormal liver
function, including onset time and frequency, to provide more
evidence to develop practical management guidelines of ATLI.
Strength and limitation
The major strength of this study included the large sample
size and the well-established ADACS follow-up processes, which
enabled us to estimate the incidence rate of ATLI and more
importantly generalize the results to similar populations under
certain conditions. In addition, diagnosis of ATLI is difficult be-
cause it requires the ruling out of other possibilities such as viral
hepatitis or other possible causes of hepatotoxicity. The causality
assessment was rarely conducted in previous studies in China, which
might have lead to the misclassification of diagnosis. By contrast, in
this study, the criteria for ATLI diagnosis and severity assessment
were based on the main concepts of ATS and WHO. Each
suspected ATLI case was strictly reviewed and assessed by experts
from CDR to ensure the accuracy of ATLI diagnosis. Thirdly, this
study reported and analyzed for the first time the impact of ATLI on
anti-TB treatment based on a large-scale population-based cohort.
There were a few limitations in our study. Firstly, there were
1,817 non-responders who met the criteria for participation and
129 patients who dropped out during the monitoring period. The
major reasons for non-responders were due to job relocation and
subjects who could not continue to participate in the study. How-
ever, when comparing the difference in terms of age and sex
among the 4,304 remainders, the 1,817 non-responders and 129
patients who dropped out of the study were no statistically signifi-
cant. Secondly, although ad-hoc tests were given to patients who
are suspected of having ATLI, the two routine tests might limit the
ability of the study to detect ATLI, in addition to detecting it
earlier. Thirdly, the study did not collect patients’ information on
prior history of hepatitis C infection and alcohol consumption,
which are risk factors for hepatotoxicity.
Conclusion
This is the first large-scale population-based cohort study to
estimate the incidence and impact of ATLI in China. The study
indicated that the cumulative incidence of ATLI is 2.55% in Chinese
TB patients receiving DOTS treatment. ATLI could considerably
impact the anti-TB treatment, potentially leading to unsuccessful
treatment outcomes and the prolongation of intensive treatment
phase. Furthermore, one-third of ATLI patients were found with no
symptoms, suggesting that monitoring liver function and identifying
known risk factors of ATLI in addition to the symptoms themselves
are critical supplements in diagnosing patients with ATLI. Given the
incidence of ATLI and the size of the TB population in China, the
negative impact of ATLI on anti-TB treatment is substantial.
Therefore, more research and efforts are warranted in order to
enhance the diagnosis and the prevention of ATLI.
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